Gilead Sciences Inc (NASDAQ:GILD) shares traded -0.22% down during most recent session to reach at the closing price of $67.94. The stock exchanged hands 5.77 Million shares versus average trading capacity of 7.93 Million shares, yielding a market cap of $88.05 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $87.06 within the next 52-weeks. The mean target projections are based on 22 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Gilead Sciences Inc (NASDAQ:GILD) high price target of $120 and with a conservative view have low price target of $71.

Oppenheimer “Upgrades” Gilead Sciences Inc (NASDAQ:GILD) in a research note issued to investors on 1/03/19 to Outperform with price target of $0.

Additionally on 12/19/18 Morgan Stanley “Maintained” Gilead Sciences Inc (NASDAQ:GILD) to Equal-Weight setting price target at $86 and on 12/17/18 Guggenheim “Reinstates” the stock to Buy at $86. Furthermore on 10/26/18 Raymond James “Maintained” the stock to Strong Buy at $94.

On the other hand the company has Relative Strength Index (RSI 14) of 55 along with Average True Range (ATR 14) of 2.34, Consequently Gilead Sciences Inc (NASDAQ:GILD)’s weekly and monthly volatility is 2.78%, 3.51% respectively. The company’s beta value is at 1.13.

In terms of Buy, Sell or Hold recommendations, Gilead Sciences Inc (NASDAQ:GILD) has analysts’ mean recommendation of 2.2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Gilead Sciences Inc (NASDAQ:GILD)’s minimum EPS for the current quarter is at $1.43 and can go high up to $2.13. The consensus mean EPS for the current quarter is at $1.7 derived from a total of 22 estimates from the analysts who have weighed in on projected earnings. However the company reported $1.78 earnings per share for the same quarter during last year.

Previously Gilead Sciences Inc (NASDAQ:GILD) reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The company posted an earnings surprise of 12.9%.

Gilead Sciences Inc (NASDAQ:GILD)’s revenue estimates for the current quarter are $5.48 Billion according to 19 number of analysts, for the current quarter the company has high revenue estimates of $5.74 Billion in contradiction of low revenue estimates of $5.06 Billion. For the current year the company’s revenue estimates are $21.77 Billion compared to low analyst estimates of $21.1 Billion and high estimates of $22.11 Billion according to 24 number of analysts.

Currently Gilead Sciences Inc (NASDAQ:GILD)’s shares owned by insiders are 0.4%, whereas shares owned by institutional owners are 81.5%. However the six-month change in the insider ownership was recorded -4.6%, as well as three-month change in the institutional ownership was recorded 0.1%.

Gilead Sciences Inc (NASDAQ:GILD)’s trailing twelve month revenues are $22.28 Billion, whereas its price to sales ratio for the same period is 3.95. Its book value per share for the most recent quarter is $17.64 while its price to book ratio for the same period is 3.85, as for as the company’s cash per share for the most recent quarter is $21.96, however its price to cash per share ratio for the same period is 3.09. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 12.59.